Last reviewed · How we verify
V-Endo
At a glance
| Generic name | V-Endo |
|---|---|
| Sponsor | Immunitor LLC |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Endometriosis and Peritoneal Dysbiosis (NA)
- Detect V / CHEVENDO (Chemo vs. Endo) (PHASE3)
- Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite) (PHASE2)
- Evaluation of New Biomarkers in Stage 3 and 4 Endometriosis
- Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF (PHASE4)
- Stapler-less Burst Pressure in a Ex-vivo Human Gastric Tissue (NA)
- Open Label Immunotherapy of Endometriosis (PHASE2)
- Barbed Sutures Versus Conventional Sutures in Laparoscopic Excision of Endometrioma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- V-Endo CI brief — competitive landscape report
- V-Endo updates RSS · CI watch RSS
- Immunitor LLC portfolio CI